Cargando…

Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma

There is no useful biomarker to evaluate treatment response and early relapse in head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual diseases and monitoring treatment effect. We investigated whether individualized ctDNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kogo, Ryunosuke, Manako, Tomomi, Iwaya, Takeshi, Nishizuka, Satoshi, Hiraki, Hayato, Sasaki, Yasushi, Idogawa, Masashi, Tokino, Takashi, Koide, Ayaka, Komune, Noritaka, Yasumatsu, Ryuji, Nakagawa, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636504/
https://www.ncbi.nlm.nih.gov/pubmed/35352507
http://dx.doi.org/10.1002/cam4.4726
_version_ 1784824958086545408
author Kogo, Ryunosuke
Manako, Tomomi
Iwaya, Takeshi
Nishizuka, Satoshi
Hiraki, Hayato
Sasaki, Yasushi
Idogawa, Masashi
Tokino, Takashi
Koide, Ayaka
Komune, Noritaka
Yasumatsu, Ryuji
Nakagawa, Takashi
author_facet Kogo, Ryunosuke
Manako, Tomomi
Iwaya, Takeshi
Nishizuka, Satoshi
Hiraki, Hayato
Sasaki, Yasushi
Idogawa, Masashi
Tokino, Takashi
Koide, Ayaka
Komune, Noritaka
Yasumatsu, Ryuji
Nakagawa, Takashi
author_sort Kogo, Ryunosuke
collection PubMed
description There is no useful biomarker to evaluate treatment response and early relapse in head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual diseases and monitoring treatment effect. We investigated whether individualized ctDNA analysis could help monitor treatment response and relapse in HNSCC. Mutation analysis of tumor and peripheral blood mononuclear cell (PBMC) DNAs of 26 patients with HNSCC was performed using a custom squamous cell carcinoma (SCC) panel. The identified individualized mutated genes were defined as ctDNA candidates. We investigated whether frequent ctDNA monitoring via digital PCR (dPCR) is clinically valid for HNSCC patients. TP53 was the most frequently mutated gene and was detected in 14 of 24 cases (58.2%), wherein two cases were excluded owing to the absence of tumor‐specific mutations in the SCC panel. Six cases were excluded because of undesignable and unusable primer‐probes for dPCR. Longitudinal ctDNA was monitored in a total of 18 cases. In seven cases, ctDNA tested positive again or did not test negative, and all seven cases relapsed after initial curative treatment. In 11 cases, after initial curative treatment, ctDNA remained negative and patients were alive without recurrence. Patients who remained negative for ctDNA during follow‐up after initial curative treatment (n = 11) had a significantly better prognosis than those who reverted to ctDNA positivity (n = 7; p < 0.0001; log‐rank test). Individualized ctDNA monitoring using SCC panel and dPCR might be a novel and promising biomarker for HNSCC.
format Online
Article
Text
id pubmed-9636504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96365042022-11-07 Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma Kogo, Ryunosuke Manako, Tomomi Iwaya, Takeshi Nishizuka, Satoshi Hiraki, Hayato Sasaki, Yasushi Idogawa, Masashi Tokino, Takashi Koide, Ayaka Komune, Noritaka Yasumatsu, Ryuji Nakagawa, Takashi Cancer Med RESEARCH ARTICLES There is no useful biomarker to evaluate treatment response and early relapse in head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual diseases and monitoring treatment effect. We investigated whether individualized ctDNA analysis could help monitor treatment response and relapse in HNSCC. Mutation analysis of tumor and peripheral blood mononuclear cell (PBMC) DNAs of 26 patients with HNSCC was performed using a custom squamous cell carcinoma (SCC) panel. The identified individualized mutated genes were defined as ctDNA candidates. We investigated whether frequent ctDNA monitoring via digital PCR (dPCR) is clinically valid for HNSCC patients. TP53 was the most frequently mutated gene and was detected in 14 of 24 cases (58.2%), wherein two cases were excluded owing to the absence of tumor‐specific mutations in the SCC panel. Six cases were excluded because of undesignable and unusable primer‐probes for dPCR. Longitudinal ctDNA was monitored in a total of 18 cases. In seven cases, ctDNA tested positive again or did not test negative, and all seven cases relapsed after initial curative treatment. In 11 cases, after initial curative treatment, ctDNA remained negative and patients were alive without recurrence. Patients who remained negative for ctDNA during follow‐up after initial curative treatment (n = 11) had a significantly better prognosis than those who reverted to ctDNA positivity (n = 7; p < 0.0001; log‐rank test). Individualized ctDNA monitoring using SCC panel and dPCR might be a novel and promising biomarker for HNSCC. John Wiley and Sons Inc. 2022-03-30 /pmc/articles/PMC9636504/ /pubmed/35352507 http://dx.doi.org/10.1002/cam4.4726 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Kogo, Ryunosuke
Manako, Tomomi
Iwaya, Takeshi
Nishizuka, Satoshi
Hiraki, Hayato
Sasaki, Yasushi
Idogawa, Masashi
Tokino, Takashi
Koide, Ayaka
Komune, Noritaka
Yasumatsu, Ryuji
Nakagawa, Takashi
Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
title Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
title_full Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
title_fullStr Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
title_full_unstemmed Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
title_short Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
title_sort individualized circulating tumor dna monitoring in head and neck squamous cell carcinoma
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636504/
https://www.ncbi.nlm.nih.gov/pubmed/35352507
http://dx.doi.org/10.1002/cam4.4726
work_keys_str_mv AT kogoryunosuke individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT manakotomomi individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT iwayatakeshi individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT nishizukasatoshi individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT hirakihayato individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT sasakiyasushi individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT idogawamasashi individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT tokinotakashi individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT koideayaka individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT komunenoritaka individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT yasumatsuryuji individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma
AT nakagawatakashi individualizedcirculatingtumordnamonitoringinheadandnecksquamouscellcarcinoma